GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (HKSE:04332) » Definitions » Common Stock

Amgen (HKSE:04332) Common Stock : HK$258,270 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Amgen Common Stock?

Amgen's quarterly common stock increased from Jun. 2023 (HK$255,364 Mil) to Sep. 2023 (HK$256,407 Mil) and increased from Sep. 2023 (HK$256,407 Mil) to Dec. 2023 (HK$258,270 Mil).

Amgen's annual common stock increased from Dec. 2021 (HK$250,317 Mil) to Dec. 2022 (HK$253,134 Mil) and increased from Dec. 2022 (HK$253,134 Mil) to Dec. 2023 (HK$258,270 Mil).

Amgen Common Stock Historical Data

The historical data trend for Amgen's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Common Stock Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 246,083.69 246,525.92 250,316.70 253,134.50 258,270.09

Amgen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 253,134.50 255,357.46 255,363.63 256,406.86 258,270.09

Amgen Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Amgen (HKSE:04332) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (HKSE:04332) » Definitions » Common Stock
Comparable Companies
PFE BMY GILD BIIB OGN AMRN SCLX MIRA ABBV MRK LLY JNJ LSE:AZN XSWX:ROG XSWX:NOVN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276
Traded in Other Exchanges
AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Website
https://www.amgen.com
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (HKSE:04332) Headlines

No Headlines